Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9597281 | MYLAN SPECIALITY LP | Pharmaceutical formulations useful in the treatment of insomnia |
Apr, 2027
(3 years from now) | |
US9265720 | MYLAN SPECIALITY LP | Pharmaceutical formulations useful in the treatment of insomnia |
Feb, 2031
(7 years from now) |
Market Authorisation Date: 13 March, 2009
Treatment: Method of treating insomnia characterized by difficulty with sleep onset
Dosage: TABLET;SUBLINGUAL
5
United States
2
Slovenia
2
Cyprus
2
Denmark
2
Portugal
2
Poland
2
United Kingdom
2
Lithuania
2
European Union
1
Hungary
1
Spain
1
Japan
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7682628 | PURDUE PHARMA | Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof |
Feb, 2025
(1 year, 8 months from now) | |
US8252809 | PURDUE PHARMA | Compositions for treating insomnia |
Feb, 2025
(1 year, 8 months from now) | |
US7658945 | PURDUE PHARMA | Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof |
Apr, 2027
(3 years from now) | |
US8242131 | PURDUE PHARMA | Methods of treating middle-of-the-night insomnia |
Aug, 2029
(6 years from now) |
Market Authorisation Date: 23 November, 2011
Treatment: Method for treating insomnia; Method of treating middle-of-the-night insomnia
Dosage: TABLET;SUBLINGUAL
31
United States
8
Korea, Republic of
3
Canada
3
Japan
2
Mexico
2
Brazil
2
China
2
New Zealand
2
South Africa
2
Australia
2
European Union
1
Israel
1
Hong Kong
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8236285 | AYTU | Buccal, polar and non-polar spray containing zolpidem |
Aug, 2032
(9 years from now) |
Market Authorisation Date: 19 December, 2008
Treatment: Treatment of transient insomnia
Dosage: SPRAY, METERED;ORAL
80
United States
24
European Union
15
Canada
13
Japan
10
Australia
4
New Zealand
2
Korea, Republic of
1
Germany
1
Spain
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic